Abstract
The crystallinity of drug-loaded lipid nanoparticles is believed to affect drug release rates; however, effective control over lipid crystallinity has not been achieved by current lipid nanoparticle preparation methods. The present study investigates control over the crystallinity of drug-loaded nanoparticle aerosol lipid matrices (NALM) through differences in evaporation rates of precursor solution drops and the subsequent control over drug release rates from these matrices. Gefitinib-loaded NALM were synthesized in an aerosol reactor using precursor solutions of gefitinib and stearic acid at a ratio of 1:4 w/w in organic solvents with high (dichloromethane) and low (ethyl acetate and chloroform) vapor pressures. Mean mobility diameter measured using a scanning mobility particle sizer was in the range of 123–132nm with a unimodal distribution and a geometric standard deviation of 1.6–1.9. A layered particle structure was observed using transmission electron microscopy, which suggests partial drug enrichment in the surface layer. Higher drug loading (20% w/w) and uniform entrapment efficiencies (∼100%) were achieved. The initial drug to lipid ratio (1:4 w/w) of the precursor solution was preserved in the synthesized lipid matrices. The crystallinity of the gefitinib-loaded lipid matrix was measured using X-ray diffraction and differential scanning calorimetry. In vitro drug release from gefitinib-loaded NALM in phosphate buffered saline (pH 7.2) over 10 days showed an initial fast release period followed by a prolonged sustained release period with varying release rates. Gefitinib-loaded NALM synthesized at higher evaporation rates exhibited lower degrees of crystallinity and faster drug releases. These results suggest the determinant role of lipid crystallinity manipulated by differing evaporation rates during aerosol synthesis on drug releases from nanometer-sized lipid matrices.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.